Unknown PHASE1 INTERVENTIONAL NCT00004036

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells

Sponsor: The Cleveland Clinic

Conditions Chronic Myeloproliferative Disorders Drug/Agent Toxicity by Tissue/Organ Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Precancerous Condition Unspecified Adult Solid Tumor, Protocol Specific

Interventions amifostine trihydrate carboplatin cyclophosphamide sargramostim

Updated 5 times since 2017 Last updated: Dec 18, 2013 Started: Nov 30, 1997

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Chronic Myeloproliferative Disorders and Drug/Agent Toxicity by Tissue/Organ, this trial is ongoing. The trial is conducted by The Cleveland Clinic and has accumulated 5 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Nov 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Cleveland Clinic

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States